MA49069A - Procédés et compositions pour le traitement d'apnée du sommeil - Google Patents

Procédés et compositions pour le traitement d'apnée du sommeil

Info

Publication number
MA49069A
MA49069A MA049069A MA49069A MA49069A MA 49069 A MA49069 A MA 49069A MA 049069 A MA049069 A MA 049069A MA 49069 A MA49069 A MA 49069A MA 49069 A MA49069 A MA 49069A
Authority
MA
Morocco
Prior art keywords
compositions
treatment
methods
sleep apnea
apnea
Prior art date
Application number
MA049069A
Other languages
English (en)
Inventor
Luigi Taranto-Montemurro
D Andrew Wellman
Original Assignee
Brigham & Womens Hospital Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=63918622&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA49069(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Brigham & Womens Hospital Inc filed Critical Brigham & Womens Hospital Inc
Publication of MA49069A publication Critical patent/MA49069A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/222—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having aromatic groups, e.g. dipivefrine, ibopamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pulmonology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
MA049069A 2017-04-28 2018-04-26 Procédés et compositions pour le traitement d'apnée du sommeil MA49069A (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762491504P 2017-04-28 2017-04-28
US201762558814P 2017-09-14 2017-09-14
PCT/US2018/029518 WO2018200775A1 (fr) 2017-04-28 2018-04-26 Procédés et compositions pour le traitement d'apnée du sommeil

Publications (1)

Publication Number Publication Date
MA49069A true MA49069A (fr) 2020-03-04

Family

ID=63918622

Family Applications (1)

Application Number Title Priority Date Filing Date
MA049069A MA49069A (fr) 2017-04-28 2018-04-26 Procédés et compositions pour le traitement d'apnée du sommeil

Country Status (22)

Country Link
US (3) US11123313B2 (fr)
EP (1) EP3615016A4 (fr)
JP (2) JP7373997B2 (fr)
KR (1) KR20240042261A (fr)
CN (1) CN110799181A (fr)
AU (2) AU2018260666B2 (fr)
BR (1) BR112019022483A2 (fr)
CA (1) CA3061468A1 (fr)
CO (1) CO2019013180A2 (fr)
CR (1) CR20190546A (fr)
DO (1) DOP2019000274A (fr)
EC (1) ECSP19084058A (fr)
GE (2) GEP20227387B (fr)
MA (1) MA49069A (fr)
MX (2) MX2019012729A (fr)
MY (1) MY200172A (fr)
NI (1) NI201900110A (fr)
PH (1) PH12019502427A1 (fr)
SG (2) SG10202111623TA (fr)
UA (1) UA127759C2 (fr)
WO (1) WO2018200775A1 (fr)
ZA (1) ZA201907158B (fr)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2018260666B2 (en) * 2017-04-28 2022-07-21 The Brigham And Women's Hospital, Inc. Methods and compositions for treating sleep apnea
AU2019214891A1 (en) * 2018-01-30 2020-08-20 Apnimed, Inc. (Delaware) Methods and compositions for treating sleep apnea
CN108309261B (zh) * 2018-02-11 2020-05-22 西安交通大学 一种猝死预警方法及装置和系统
US20190381056A1 (en) 2018-06-17 2019-12-19 Axsome Therapeutics, Inc. Compositions for delivery of reboxetine
WO2020091862A1 (fr) * 2018-10-31 2020-05-07 Apnimed, Inc. (Delaware) Méthodes et compositions pour le traitement de l'apnée du sommeil
AU2020219809A1 (en) * 2019-02-08 2021-08-19 The Brigham And Women's Hospital, Inc. Methods and compositions for treating sleep apnea
WO2021091902A1 (fr) * 2019-11-04 2021-05-14 Apnimed, Inc. (Delaware) Interventions pharmacologiques combinées pour des mécanismes multiples d'apnée obstructive du sommeil
RU2757470C1 (ru) * 2020-11-19 2021-10-18 Ренат Рашитович Ахмеров Способ лечения храпа с помощью введения тромбоцитарной аутологичной плазмы
WO2022155162A1 (fr) * 2021-01-14 2022-07-21 Apnimed, Inc. (Delaware) Méthodes et compositions pour traiter l'apnée du sommeil
CA3210092A1 (fr) * 2021-03-04 2022-09-09 Lawrence G. Miller Combinaison de reboxetine et d'un antagoniste du recepteur muscarinique (arm) destinee a etre utilisee dans le traitement de l'apnee du sommeil
WO2022221613A1 (fr) * 2021-04-16 2022-10-20 Apnimed, Inc. (Delaware) Combinaison d'un inhibiteur de recaptage de la norépinéphrine et d'un cannabinoïde pour une utilisation dans le traitement de l'apnée du sommeil
KR20240021920A (ko) * 2021-06-17 2024-02-19 애프니메드, 인코포레이티드 (델라웨어) 수면 무호흡증을 치료하기 위한 노르에피네프린 재흡수 억제제
WO2023034265A1 (fr) * 2021-08-31 2023-03-09 Apnimed, Inc. (Delaware) Méthodes et compositions pour le traitement de l'apnée du sommeil
TW202342011A (zh) 2021-12-22 2023-11-01 德商拜耳廠股份有限公司 用於治療睡眠呼吸中止之α２－腎上腺素受體亞型Ｃ（α－２Ｃ）拮抗劑與蕈毒鹼受體拮抗劑之組合
TW202342052A (zh) * 2021-12-22 2023-11-01 德商拜耳廠股份有限公司 用於治療睡眠呼吸中止之ｔａｓｋ１／３通道阻斷劑與正腎上腺素再吸收抑制劑之組合
WO2023118123A1 (fr) 2021-12-22 2023-06-29 Bayer Aktiengesellschaft Combinaison d'un antagoniste alpha 2-adrénocepteur de sous-type c (alpha -2c) avec un inhibiteur de recaptage de norépinéphrine pour le traitement de l'apnée du sommeil
WO2023219991A1 (fr) * 2022-05-13 2023-11-16 Apnimed, Inc. (Delaware) Méthodes et compositions pour le traitement de l'apnée du sommeil

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU767877B2 (en) 1999-05-20 2003-11-27 Sepracor, Inc. Methods for treatment of asthma using S-oxybutynin
JP2003523382A (ja) 2000-02-24 2003-08-05 ファルマシア・アンド・アップジョン・カンパニー 新規な薬物の組合せ
US20060039867A1 (en) 2004-08-20 2006-02-23 Cypress Bioscience, Inc. Method for treating sleep-related breathing disorders with setiptiline
JP2008524332A (ja) * 2004-12-20 2008-07-10 コレジウム ファーマシューティカル， インク． 睡眠傷害のための医薬組成物
US8753327B2 (en) * 2011-01-28 2014-06-17 Pfantastic Medical Research Institute, Llc Methods for treating obstructive sleep apnea
AU2018260666B2 (en) * 2017-04-28 2022-07-21 The Brigham And Women's Hospital, Inc. Methods and compositions for treating sleep apnea
AU2019214891A1 (en) 2018-01-30 2020-08-20 Apnimed, Inc. (Delaware) Methods and compositions for treating sleep apnea

Also Published As

Publication number Publication date
MX2019012729A (es) 2019-12-19
JP7373997B2 (ja) 2023-11-06
CR20190546A (es) 2020-04-08
NZ758564A (en) 2023-12-22
GEP20227387B (en) 2022-06-10
ZA201907158B (en) 2021-09-29
SG10202111623TA (en) 2021-12-30
NI201900110A (es) 2020-03-18
US11123313B2 (en) 2021-09-21
MX2022010349A (es) 2022-09-19
US20210401777A1 (en) 2021-12-30
PH12019502427A1 (en) 2020-10-05
WO2018200775A1 (fr) 2018-11-01
GEP20247617B (en) 2024-04-25
CA3061468A1 (fr) 2018-11-01
AU2022241471A1 (en) 2022-10-27
AU2018260666A1 (en) 2019-11-14
JP2023139000A (ja) 2023-10-03
MY200172A (en) 2023-12-12
CO2019013180A2 (es) 2020-02-07
CN110799181A (zh) 2020-02-14
KR20190140019A (ko) 2019-12-18
DOP2019000274A (es) 2019-12-30
JP2020517719A (ja) 2020-06-18
BR112019022483A2 (pt) 2020-05-12
EP3615016A1 (fr) 2020-03-04
UA127759C2 (uk) 2023-12-27
SG11201909973UA (en) 2019-11-28
AU2018260666B2 (en) 2022-07-21
EP3615016A4 (fr) 2021-02-24
ECSP19084058A (es) 2020-01-31
US20240189261A1 (en) 2024-06-13
US20200054583A1 (en) 2020-02-20
KR20240042261A (ko) 2024-04-01

Similar Documents

Publication Publication Date Title
MA49069A (fr) Procédés et compositions pour le traitement d'apnée du sommeil
MA52861A (fr) Méthodes et compositions pour le traitement de l'apnée du sommeil
MA42819A (fr) Procédés pour le traitement d'infections virales à arenaviridae et coronaviridae
MA50849A (fr) Substances et procédés pour le traitement d'hémoglobinopathies
MA45798A (fr) Compositions et procédés d'inhibition de masp-3 pour le traitement de maladies et troubles divers
MA51103A (fr) Compositions et procédés de traitement de l'atrophie musculaire et de la dystrophie myotonique
MA51796A (fr) Procédés et compositions pour l'administration de protéines thérapeutiques
MA51306A (fr) Compositions et procédés améliorés pour le traitement du déficit en ornithine transcarbamylase
MA43283A (fr) Procédés et compositions pour le traitement du cancer
MA50636A (fr) Compositions et procédés pour inhiber l'activité d'arginase
MA54609A (fr) Inhibiteurs aza-hétérobicycliques de mat2a et procédés d'utilisation pour le traitement du cancer
MA54608A (fr) Inhibiteurs aza-hétérobicycliques de mat2a et procédés d'utilisation pour le traitement du cancer
MA45270A (fr) Compositions d'oligonucléotides et procédés associés
MA53558A (fr) Compositions et procédés pour le traitement d'infections virales
SG11202011296VA (en) Compositions and methods for the treatment of parkinson's disease
MA51056A (fr) Compositions et méthodes pour le traitement d'affections métaboliques
MA43170A (fr) Association d'un inhibiteur de bcl-2 et d'un inhibiteur de mek pour le traitement du cancer
MA53873A (fr) Compositions et procédés pour le traitement de la presbytie
MA49576A (fr) Compositions et méthodes pour le traitement d'infections fongiques
IL274578A (en) Pharmaceutical compounds and preparations thereof for use in the treatment of leiftic diseases
MA44700A (fr) Combinaison d'un anticorps anti-il-10 et d'un oligonucléotide de type cpg-c pour le traitement du cancer
MA52199A (fr) Compositions et procédés de traitement de la dystrophie maculaire
MA43825A (fr) Schémas posologiques pour le traitement d'infections fongiques
MA42497A (fr) Procédés et compositions pour la régulation sélective de l'expression protéique
MA41629A (fr) Compositions et méthodes d'utilisation de l'hormone anti-müllérienne pour le traitement de l'infertilité